OBJECTIVE: This study was designed to validate an established claims-based persistent asthma severity classification using clinical parameters abstracted from medical charts. METHODS: Patients with asthma, aged 6-64 years, were selected from a claims database (1999)(2000)(2001)(2002)(2003)(2004)(2005) of a medical group practice organization located in central Massachusetts. Patients had persistent asthma defined using an established algorithm; no chronic obstructive pulmonary disease; and at least one procedure code for spirometry. All recorded pre-broncodilator values of FEV1 or PEF, height, and weight were extracted from medical charts. Patients' asthma severity was categorized based on two methods: an established claims-based algorithm and guidelines classification algorithm based on clinical parameters. Gamma rank correlation index was used to measure the association between the two severity categorization methods. One year total and asthmarelated costs for each severity category were also compared between the two different approaches. RESULTS: Based on claims-based severity classification, 41% of 368 patients in the study sample had mild persistent asthma, 33.7% had moderate, and 25% had severe. Using clinical parameters (% predicted FEV1 or PEF value), 68.2% of patients had mild, 23.9% had moderate, and 7.9% had severe persistent asthma. The correlation between the two classification approaches was statistically significant (P = 0.0002). Patients with higher severity generally had higher costs. Comparing the two classification approaches, patients with moderate persistent asthma using the clinical parameters approach had significantly higher asthma-related direct costs ($2395) than those classified as having moderate persistent asthma using the claims-based approach ($1604). There were no significant asthma-related cost differences in mild and severe asthma categories. CONCLUSION: While more patients were classified into higher severity level using a claimsbased classification approach than clinical parameters, the two classification methods exhibited significant association. The claims-based algorithm can be helpful in economic studies in asthma patients where classifying asthma severity using claims is needed. OBJECTIVE: To estimate patient preferences for improvements in onset of effect of asthma combination maintenance medications. METHODS: The Onset-of-Effect Questionnaire (OEQ) is a self-administered instrument used to assess patient satisfaction with how quickly asthma maintenance medications begin to work. The OEQ elicits subject ratings for five statements: "I could tell the medication was working" (Medication Works), "I could feel the medication begin to work right away" (Works Right Away), "I felt physical sensations shortly after taking the medication that reassured me it was working" (Physical Sensations), "The medication worked as quickly as my rescue medication" (Rescue), and "I was satisfied with how quickly I felt the medication begin to work" (Satisfied). Asthma patients,18 years and older, currently using combination maintenance therapy, completed an online survey instrument that included 10 statedchoice trade-off tasks. Subjects chose among pairs of hypothetical medication alternatives, each defined by responses by "people like you" to the five OEQ statements and monthly out-of-pocket cost, or their current treatment. We used mixed-logit methods to estimate dollar value-to-patient (VTP) per month for various improvements in maintenance-medication onset of effect. RESULTS: A total of 509 subjects completed the survey. Responses demonstrated a high level of internal validity. "Satisfied" was the most important attribute and "Physical Sensations" the least important attribute. Improvement from "Strongly Disagree" to "Strongly Agree" on Works Right Away was preferred by 62% (95%CI: 57-67%) of patients. Improvement from "Strongly Disagree" to "Strongly Agree" on Satisfied was preferred by, 80% (95% CI: 75-85%) of patients with a mean VTP (95% CI) of $20 ($17-$24). CONCLUSION: The results of this study demonstrate that onset of effect, particularly patients' ability to feel the medication begin to work right away and patients' satisfaction with how quickly they feel the medication being to work, are of significant value to asthma patients. OBJECTIVE: To determine if differences in perceived onset of effect (OE) in asthma patients were clinically meaningful from the perspective of clinicians. METHODS: Data from two clinical trials (SD-039-0716 and SD-039-0717) of asthmatic patients randomized to either budesonide/formoterol pMDI or placebo were utilized in a Delphi consensus approach to identify a threshold for clinically important differences in patient-perceived OE within the context of the trials. Twelve community-based clinicians, including 3 allergists, 3 pulmonologists, 3 general practitioners, and 3 nurses, who spent at least 50% of their time in clinical practice and treated at least 3 patients with asthma per week, were recruited to participate on the Delphi panel. Panelists were asked to determine: 1) whether results of patient-perceived OE were clinically meaningful; 2) the minimum acceptable difference between active and placebo response, assuming a 25% placebo response; and 3) the maximum acceptable placebo effect. The panel participated in two rounds of the Delphi process. RESULTS: There was unanimity from panelists that results from the clinical trials whereby a significantly larger percentage of patients (69% and 75% for moderate-to-severe and mild-tomoderate asthma patients, respectively) treated with budesonide/ formoterol pMDI reported that they could feel their medication begin to work right away compared to placebo (23% and 26% for moderate-to-severe and mild-to-moderate asthma patients, respectively) were clinically meaningful. The consensus results for minimum active treatment response with a 25% placebo effect ranged from 50% to 70%, while the consensus for maximum placebo effect ranged from 30% to 40% for patientperceived OE. CONCLUSION: Differences in perceived OE between asthma patients taking budesonide/formoterol pMDI and those taking placebo were considered clinically meaningful by the panel.
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Mohamed AF 1 , Johnson FR 1 , Hauber AB 1 , Meddis D 2 , Wagner S 2 1 RTI Health Solutions, Research Triangle Park, NC, USA, 2 AstraZeneca, Wilmington, DE, USA OBJECTIVE: To estimate patient preferences for improvements in onset of effect of asthma combination maintenance medications. METHODS: The Onset-of-Effect Questionnaire (OEQ) is a self-administered instrument used to assess patient satisfaction with how quickly asthma maintenance medications begin to work. The OEQ elicits subject ratings for five statements: "I could tell the medication was working" (Medication Works), "I could feel the medication begin to work right away" (Works Right Away), "I felt physical sensations shortly after taking the medication that reassured me it was working" (Physical Sensations), "The medication worked as quickly as my rescue medication" (Rescue), and "I was satisfied with how quickly I felt the medication begin to work" (Satisfied). Asthma patients,18 years and older, currently using combination maintenance therapy, completed an online survey instrument that included 10 statedchoice trade-off tasks. Subjects chose among pairs of hypothetical medication alternatives, each defined by responses by "people like you" to the five OEQ statements and monthly out-of-pocket cost, or their current treatment. We used mixed-logit methods to estimate dollar value-to-patient (VTP) per month for various improvements in maintenance-medication onset of effect. RESULTS: A total of 509 subjects completed the survey. Responses demonstrated a high level of internal validity. "Satisfied" was the most important attribute and "Physical Sensations" the least important attribute. Improvement from "Strongly Disagree" to "Strongly Agree" on Works Right Away was preferred by 62% (95%CI: 57-67%) of patients. Improvement from "Strongly Disagree" to "Strongly Agree" on Satisfied was preferred by, 80% (95% CI: 75-85%) of patients with a mean VTP (95% CI) of $20 ($17-$24). CONCLUSION: The results of this study demonstrate that onset of effect, particularly patients' ability to feel the medication begin to work right away and patients' satisfaction with how quickly they feel the medication being to work, are of significant value to asthma patients.
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Harding G 1 , Leidy NK 1 , Kleinman L 1 , Meddis D 2 , Wagner S 2 1 United BioSource Corporation, Bethesda, MD, USA, 2 AstraZeneca, Wilmington, DE, USA OBJECTIVE: To determine if differences in perceived onset of effect (OE) in asthma patients were clinically meaningful from the perspective of clinicians. METHODS: Data from two clinical trials (SD-039-0716 and SD-039-0717) of asthmatic patients randomized to either budesonide/formoterol pMDI or placebo were utilized in a Delphi consensus approach to identify a threshold for clinically important differences in patient-perceived OE within the context of the trials. Twelve community-based clinicians, including 3 allergists, 3 pulmonologists, 3 general practitioners, and 3 nurses, who spent at least 50% of their time in clinical practice and treated at least 3 patients with asthma per week, were recruited to participate on the Delphi panel. Panelists were asked to determine: 1) whether results of patient-perceived OE were clinically meaningful; 2) the minimum acceptable difference between active and placebo response, assuming a 25% placebo response; and 3) the maximum acceptable placebo effect. The panel participated in two rounds of the Delphi process. RESULTS: There was unanimity from panelists that results from the clinical trials whereby a significantly larger percentage of patients (69% and 75% for moderate-to-severe and mild-tomoderate asthma patients, respectively) treated with budesonide/ formoterol pMDI reported that they could feel their medication begin to work right away compared to placebo (23% and 26% for moderate-to-severe and mild-to-moderate asthma patients, respectively) were clinically meaningful. The consensus results for minimum active treatment response with a 25% placebo effect ranged from 50% to 70%, while the consensus for maximum placebo effect ranged from 30% to 40% for patientperceived OE. CONCLUSION: Differences in perceived OE between asthma patients taking budesonide/formoterol pMDI and those taking placebo were considered clinically meaningful by the panel.
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